 |
 |
Journal articles
Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.
Abstract : The tumor-associated glycoprotein 72 (TAG-72) is a membrane mucin whose over-expression is correlated with advanced tumor stage and increased invasion and metastasis. In this study, we identified a panel of four nanobodies, single variable domains of dromedary heavy-chain antibodies that specifically recognize the TAG-72 antigen. All selected nanobodies were shown to selectively bind to this cancer-related molecule with low-nanomolar affinities and do not cross-react with other antigens, such as MUC1 or HER2. Furthermore, they can detect TAG-72 in concentrations as low as 5 U/ml which is valuable in sensitive detection of this molecule in cancerous patients. Cell ELISA experiments proved their ability for binding to the native target antigen on TAG-72 expressing cells while not showing any reactivity to HT-29 cells, a TAG-72-negative cell line. Using competition studies, we found that each nanobody recognizes a distinct epitope on the TAG-72 antigen that is different from the one recognized by the mouse anti-TAG-72 antibody, CC49. Considering their high specificity, reduced immunogenicity and multi-targeting behavior, these oligoclonal nanobodies represent a promising tool to target TAG-72 over-expressing tumor cells.
Cited literature [43 references]
https://hal-riip.archives-ouvertes.fr/pasteur-00825965
Contributor : Fereidoun Mahboudi <>
Submitted on : Saturday, May 25, 2013 - 9:01:04 AM
Last modification on : Wednesday, October 14, 2020 - 4:10:26 AM
Long-term archiving on: : Tuesday, April 4, 2017 - 11:18:14 AM
Contributor : Fereidoun Mahboudi <>
Submitted on : Saturday, May 25, 2013 - 9:01:04 AM
Last modification on : Wednesday, October 14, 2020 - 4:10:26 AM
Long-term archiving on: : Tuesday, April 4, 2017 - 11:18:14 AM